Published in J Virol on July 01, 2006
HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol (2010) 1.90
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol (2009) 1.25
Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol (2008) 1.13
Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression. J Comp Neurol (2009) 1.09
Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol (2007) 1.06
In vivo delivery of cytoplasmic RNA virus-derived miRNAs. Mol Ther (2011) 0.93
Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J Virol (2012) 0.85
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol (2014) 0.83
Acute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1β. PLoS One (2012) 0.83
Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol (2013) 0.82
The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. J Virol (2012) 0.81
Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain. J Virol (2009) 0.81
Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J Virol (2013) 0.80
Relationship between within-host fitness and virulence in the vesicular stomatitis virus: correlation with partial decoupling. J Virol (2012) 0.79
A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses. Peptides (2013) 0.79
Cytopathogenesis of vesicular stomatitis virus is regulated by the PSAP motif of M protein in a species-dependent manner. Viruses (2012) 0.76
Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector. J Virol (2014) 0.75
Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. J Virol (2017) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A (2004) 9.00
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
High-level hepatitis B virus replication in transgenic mice. J Virol (1995) 5.81
Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature (1986) 4.81
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol (1996) 3.89
Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol (1993) 3.68
The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today (1988) 3.40
Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol (1999) 3.04
Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus. Science (1997) 2.72
VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell (2005) 2.55
Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell (2000) 2.33
The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol (2000) 1.89
Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field. Virology (1998) 1.75
Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol (1997) 1.72
Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity. Am J Epidemiol (1969) 1.52
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol (2004) 1.46
A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol (2005) 1.45
Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J Virol (2000) 1.42
Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol (2004) 1.38
Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology. J Virol (2002) 1.26
No apoptotic deaths and different levels of inductions of inflammatory cytokines in alveolar macrophages infected with influenza viruses. Virology (2004) 1.26
Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol (1997) 1.23
Th1 inflammatory response with altered expression of profibrotic and vasoactive mediators in AT1A and AT1B double-knockout mice. Am J Physiol Renal Physiol (2005) 0.90
Lethal weight loss: the focus shifts to signal transduction. Sci STKE (2002) 0.85
CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol (2008) 3.60
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology (2005) 1.74
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol (2002) 1.69
Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol (2002) 1.61
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol (2009) 1.57
Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol (2002) 1.49
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol (2004) 1.46
Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses (2004) 1.45
A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol (2005) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol (2002) 1.37
A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS One (2013) 1.37
Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol (2006) 1.34
A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol (2010) 1.33
Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol (2004) 1.28
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol (2014) 1.26
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol (2009) 1.25
Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology (2007) 1.22
Calcium phosphate transfection. Curr Protoc Mol Biol (2003) 1.22
Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol (2010) 1.14
Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression. J Comp Neurol (2009) 1.09
Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol (2011) 1.05
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol (2011) 1.05
Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent. J Immunol (2007) 1.04
Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine (2008) 1.03
SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology (2008) 1.01
CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J Immunol (2010) 0.99
Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine (2011) 0.98
Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol (2003) 0.98
Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol (2007) 0.97
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine (2008) 0.97
A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol (2012) 0.95
Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine (2009) 0.92
Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits. Vaccine (2006) 0.91
Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach. J Virol (2010) 0.91
Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J Virol (2004) 0.90
Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV). Vaccine (2006) 0.90
Identification of a region in the stalk domain of the nipah virus receptor binding protein that is critical for fusion activation. J Virol (2013) 0.88
An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine (2006) 0.88
Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication. J Virol (2009) 0.87
Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. J Virol (2003) 0.87
Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein. Clin Vaccine Immunol (2008) 0.85
Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors. Proc Natl Acad Sci U S A (2008) 0.85
Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors. Vaccine (2009) 0.85
CD62L- memory T cells enhance T-cell regeneration after allogeneic stem cell transplantation by eliminating host resistance in mice. Blood (2012) 0.84
Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. Vaccine (2012) 0.84
Recombinant vesicular stomatitis viruses encoding simian immunodeficiency virus receptors target infected cells and control infection. Virology (2005) 0.79
Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses. PLoS One (2013) 0.79
Crystallization and preliminary X-ray analysis of Chandipura virus glycoprotein G. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.78
Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. Comp Med (2008) 0.78
Development of an infectious surrogate hepatitis C virus based on a recombinant vesicular stomatitis virus expressing hepatitis C virus envelope glycoproteins and green fluorescent protein. Jpn J Infect Dis (2014) 0.75